Molecular determinants of outcomes in meningiomas

Meningiomas are the most common intracranial primary tumor in adults. Surgery is the predominant therapeutic modality for symptomatic meningiomas. Although the majority of meningiomas are benign, there exists a subset of meningiomas that are clinically aggressive. Recent advances in genetics and epi...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 12; p. 962702
Main Authors Lynes, John, Flores-Milan, Gabriel, Rubino, Sebastian, Arrington, John, Macaulay, Robert, Liu, James K. C., Beer-Furlan, Andre, Tran, Nam D., Vogelbaum, Michael A., Etame, Arnold B.
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 12.08.2022
Subjects
epigenetics
genetics
meningiomas
molecular classification
Oncology
outcomes
targeted therapy
Online AccessGet full text

Cover

More Information
Summary:Meningiomas are the most common intracranial primary tumor in adults. Surgery is the predominant therapeutic modality for symptomatic meningiomas. Although the majority of meningiomas are benign, there exists a subset of meningiomas that are clinically aggressive. Recent advances in genetics and epigenetics have uncovered molecular alterations that drive tumor meningioma biology with prognostic and therapeutic implications. In this review, we will discuss the advances on molecular determinants of therapeutic response in meningiomas to date and discuss findings of targeted therapies in meningiomas.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Edited by: Hailiang Tang, Fudan University, China
Reviewed by: Jose McFaline Figueroa, Dana–Farber Cancer Institute, United States; Kristin Huntoon, University of Texas MD Anderson Cancer Center, United States; Alessia Pellerino, University Hospital of the City of Health and Science of Turin, Italy
This article was submitted to Neuro-Oncology and Neurosurgical Oncology, a section of the journal Frontiers in Oncology
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2022.962702